ClinicalTrials.gg
Active, not recruitingNCT05210790VERIFYUpdated Oct 19, 2026Results posted

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

A Phase 3 interventional study of Rusfertide and Placebo in Polycythemia Vera, sponsored by Protagonist Therapeutics, Inc.. Active, not recruiting at 184 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Protagonist Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026Results postedStudy documents posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
293
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 179 studies in Polycythemia Vera with a site in United States — 22 open to participants now, 34 under way, 7 of them phase 3. Polycythemia Vera · United States.

Enrollment
8th of 150
293 · median 40
Started
2022
with 3 others
Phase 3
18 of 179
3 open now
Primary completion
2025-02
later than 3 of 33 live
Registered
157th of 179
by date

Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 8th largest by enrollment of the 150 interventional ones that give a count, is one of 4 that started in 2022, is one of 18 in phase 3, reaches primary completion later than 3 of the 33 other live ones, and was the 157th registered.

Polycythemia Vera

278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.

Browse Polycythemia Vera studies →

Open to participants now

22 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Polycythemia Vera with a site in United States, or all of them as a file.
02

Study summary

Polycythemia vera (PV) is a long-term condition in which the bone marrow makes too many red blood cells (RBCs). Bone marrow is the soft tissue inside the large bones where blood cells are made. When there are too many RBCs, called erythrocytosis, the blood can become thicker and move less easily through blood vessels and organs. This can raise the risk of blood clots (thrombosis) in veins or arteries. Sometimes, these clots can be life-threatening and may cause a stroke or heart attack. Treatment aims to keep the percentage of RBCs in the blood (hematocrit) in a safe range. For adults with PV, this means keeping the hematocrit below 45%. This helps lower the blood thickness and the risk of thrombosis. PV can also be linked to low iron levels (iron deficiency), because the body uses iron to make more RBCs. Many people with PV are treated with blood removal (phlebotomy) to lower RBC levels in the blood. This can worsen the iron deficiency, because each blood removal also takes iron out of the body.

Rusfertide is a medicine that lowers the amount of iron available in the blood. It works like hepcidin, a natural hormone that helps control iron levels in the body. By limiting iron available for RBC production, rusfertide may help keep hematocrit below 45% and may improve symptoms. It may also reduce, or even remove, the need for phlebotomy in people.

The main aim of this study is to check how well rusfertide works compared with placebo to lower the number of phlebotomies. A placebo looks like rusfertide but does not have any medicine in it.

Other aims are to learn how safe rusfertide is compared with placebo and to understand how well it works to reduce the need for phlebotomy and to keep hematocrit levels under control. The study also wants to learn how rusfertide moves through the body (pharmacokinetics) and how it affects the body (pharmacodynamics or PD).

This study has 4 parts that follow each other:

  • In part 1a, participants will receive either rusfertide or placebo.
  • In part 1b, all participants will receive rusfertide.
  • In part 2, participants can continue to receive rusfertide if they benefit from treatment with rusfertide.
  • Part 3 will include participants who finish Part 2 and still benefit from rusfertide.

During the study, participants will visit the study clinical several times at fixed timepoints.

03

Conditions studied

  • Polycythemia Vera

Browse trials for

Keywords

  • Polycythemia Vera
  • PV
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants aged 18 (or the minimum country specific age of consent if greater than [>]18) years or older.
  2. Participant understands the study procedures, is willing and able to adhere to study requirements and agrees to participate in the study by giving written .
  3. Meet revised 2016 World Health Organization (WHO) criteria for the diagnosis of PV.
  4. Phlebotomy requiring defined as ALL of the following:

    1. At least 3 phlebotomies due to inadequate hematocrit control in 28 weeks before randomization or at least 5 phlebotomies due to inadequate hematocrit control in 1 year before randomization, and
    2. Last phlebotomy due to inadequate hematocrit control within 3 months before randomization, and
    3. No phlebotomy within 6 days prior to randomization (do not include day of phlebotomy and day of randomization in the 6-day count).
  5. Complete blood count (CBC) values immediately prior to randomization:

    1. Hematocrit \<45%,
    2. White blood cell count (WBC) 4000 cells per microlitre (/μL) to 20,000/μL (inclusive), and
    3. 100,000/μL to 1,000,000/μL (inclusive).
  6. (ECOG) performance status 0, 1 or 2.
  7. Women of (WOCBP) agree to use medically acceptable (\<1% annual failure rate) during the study and for 30 days after the last dose of study drug.
  8. A female participant must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 30 days after receiving the last dose of study medication.
  9. Men with partners of childbearing potential agree to use medically acceptable contraception (\<1% annual failure rate) during the study and for 90 days after the last dose of study drug. In addition, men must use a condom during the study and for 90 days after the last dose of study drug regardless of the partner's childbearing potential.
  10. A male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose.
  11. Participants receiving cytoreductive therapy at randomization must be on a stable PV therapy regimen as follows:

    1. Hydroxyurea - at least 2 months
    2. Janus kinase (JAK) inhibitor - at least 2 months
    3. Interferon - at least 6 months.
  12. Participants treated with phlebotomy alone at randomization must have stopped:

    1. Hydroxyurea at least 2 months before screening
    2. JAK inhibitor at least 2 months before screening
    3. Interferon at least 6 months before screening.

Exclusion criteria

Exclusion criteria:

  1. laboratory abnormalities at Screening, including but not limited to the following:

    1. Estimated (eGFR) \<15 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2)
    2. (ALT) or aspartate aminotransferase (AST) ≥2.5× (ULN)
    3. Total >1.5×ULN
  2. Participants who required phlebotomy at HCT levels lower than 45%.
  3. Pregnant or lactating females.
  4. Clinically significant thrombosis (e.g., deep vein thrombosis or splenic vein thrombosis) within 2 months prior to randomization.
  5. Active or chronic bleeding within 2 months prior to randomization.
  6. Met the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment.
  7. Any infection requiring systemic therapy within 1 month of dosing except controlled (HIV), , and . Prophylactic therapies were allowed.
  8. Any serious or unstable medical condition (e.g., poorly controlled HIV infection) or uncontrolled psychiatric condition as judged by the Investigator that would impair the participant's ability to participate in the study.
  9. Major surgical procedure within 2 months prior to randomization unless the participant had fully recovered from surgery or planned major elective surgery during the study.
  10. History of invasive within the last 5 years, except

    1. localized cured cancer (e.g., prostate cancer and cervical cancer)
    2. localized cured in situ or Stage 1 squamous cell carcinoma (SCC) of the skin, basal cell carcinoma (BCC) of the skin, or in situ melanoma of the skin.
  11. Participants with in situ or Stage 1 SCC of the skin, in situ or Stage 1 BCC of the skin, or in situ melanoma of the skin identified during the required dermatology examination at Screening unless the cancer was adequately treated (i.e., treatment that was expected to be curative, such as Mohs surgery) before randomization. Note: Suspicious lesions were to be biopsied and results made available before randomization.
  12. Participants with active alcohol or drug addiction that would have interfered with their ability to comply with study requirements.
  13. Participants who did not complete at least 4 days of MFSAF assessments within 1 week prior to randomization.
  14. Receipt of an agent within 2 months or 5 half-lives, whichever was longer, prior to randomization.
  15. Received busulfan, pipobroman, or 32Phosphorus within 7 months prior to Screening.
  16. Participants with to rusfertide or to any of the or placebo.
  17. Participants with any lesion or mass detected by physical examination or imaging during screening that was suspicious for malignancy unless evaluated and assessed to be not malignant.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
293 participants (actual)

Study arms

  • Placebo comparator
    Part 1a: Randomized, Double-Blind Period: Placebo

    Participants received their ongoing therapy for polycythemia vera (PV) along with rusfertide-matching placebo, subcutaneous (SC) injection, once weekly, from baseline up to Week 32.

    Drug: Placebo

  • Experimental
    Part 1a: Randomized, Double-Blind Period: Rusfertide

    Participants received their ongoing therapy for PV along with rusfertide once weekly, SC injection, from baseline up to Week 32. Rusfertide doses were titrated to maintain hematocrit less than (\<) 45 percent (%). The starting dose was 19 milligrams (mg). The doses that were administered to Part 1a participants were 9.5, 19, 28, 41, 54, 69 and 82 mg.

    Drug: Rusfertide

  • Experimental
    Part 1b: Open-Label Treatment Period: Rusfertide

    Participants received rusfertide once weekly, SC injection, from Weeks 32 to 52. Rusfertide doses were titrated to maintain hematocrit \< 45%. Participants who received rusfertide in Part 1a continued at their current dose unless dose adjustment was required. Participants who received placebo in Part 1a started rusfertide at 19 mg. The doses that were administered to Part 1b participants were 9.5, 19, 28, 41, 54, 69 and 82 mg.

    Drug: Rusfertide

  • Experimental
    Part 2: Long Term Extension Period: Rusfertide

    Participants received rusfertide once weekly, SC injection, from Weeks 52 to 156. Rusfertide doses were titrated to maintain hematocrit \< 45%. The doses that were administered to Part 2 participants were 9.5, 19, 28, 41, 54, 69, 82, 95 and 108 mg. For weekly doses greater than (\>) 90 mg, the dose of rusfertide was and will be divided into 2 doses administered 3 to 4 days apart.

    Drug: Rusfertide

  • Experimental
    Part 3: Treatment Extension Period: Rusfertide

    Participants will receive rusfertide once weekly, SC injection, from Week 156 to the end of the study (approximately 5 years). Rusfertide doses will be titrated to maintain hematocrit \< 45%. The doses that will be administered to Part 3 participants are 9.5, 19, 28, 41, 54, 69, 82, 95 and 108 mg. For weekly doses \> 90 mg, the dose of rusfertide will be divided into 2 doses administered 3 to 4 days apart.

    Drug: Rusfertide

Interventions

  • Rusfertide SC injection

  • DrugPlacebo

    Rusfertide-matching placebo SC injection

06

What researchers measure

Primary outcomes

  1. Part 1a: Percentage of Participants Who Achieved Response

    Response was defined as absence of phlebotomy eligibility. Phlebotomy eligibility was defined as either: 1) A confirmed hematocrit (HCT) greater than or equal to (≥) 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

    Time frame: From Weeks 20 to 32

Secondary outcomes

  1. Part 1a: Number of Phlebotomies

    Time frame: Baseline to Week 32

  2. Part 1a: Percentage of Participants With All Hematocrit Values < 45%

    Time frame: Baseline to Week 32

  3. Part 1a: Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a Total T-score

    The PROMIS Fatigue SF 8a T-score will be obtained via the item-response theory (IRT) response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 32

  4. Part 1a: Change From Baseline in the Myelofibrosis Symptom Assessment Form (MFSAF) Version 4.0 Total Symptom Score-7 (TSS7) Items

    The MFSAF version 4.0 (v4.0) TSS7 is a questionnaire developed by the Patient-Reported Outcome (PRO) Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 32

  5. Part 1a: Change From Baseline in the PROMIS Fatigue Short Form 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at Baseline

    The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is a National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 32

  6. Part 1a: Change From Baseline in the MFSAF Total Symptom Score-4 Items (TSS4) Among Participants Who Have Moderate or Severe Symptoms at Baseline

    The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focused on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. Items are scored on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

    Time frame: Baseline, Week 32

  7. Part 1a: Change From Baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Problems With Concentration Among Participants Who Have Moderate or Severe Symptoms at Baseline

    MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as baseline MPN-SAF problems with concentration ≥4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline will be categorized using the Patient Global Impression of Severity (PGI-S). The response quartiles will be used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.

    Time frame: Baseline, Week 32

  8. Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at Baseline

    The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8.

    Time frame: At Week 32

  9. Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4 Among Participants Who Had Moderate or Severe Symptoms at Baseline

    The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It included 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1.

    Time frame: At Week 32

  10. Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With Concentration Among Participants Who Had Moderate or Severe Symptoms at Baseline

    MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as baseline MPN-SAF problems with concentration ≥4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.

    Time frame: At Week 32

  11. Change From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue SF 8a

    The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey that includes 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity.

    Time frame: Baseline to end of study (up to approximately 5 years)

  12. Change From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue Short Form 8a for Among Participants With Moderate or Severe Symptoms at Baseline

    The PROMIS Fatigue SF 8a T-score was obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is a National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8. A negative change from baseline indicates an improvement.

    Time frame: Baseline to end of study (up to approximately 5 years)

  13. Change From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MFSAF v4.0 TSS4

    The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms.

    Time frame: Baseline to end of study (up to approximately 5 years)

  14. Change From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 TSS4 Among Participants With Moderate or Severe Symptoms at Baseline

    The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focused on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. Items are scored on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

    Time frame: Baseline to end of study (up to approximately 5 years)

  15. Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-score

    The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey that includes 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. A negative change from baseline indicates an improvement.

    Time frame: At Week 32

  16. Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4

    The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive).

    Time frame: At Week 32

  17. Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With Concentration

    MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as a baseline MPN-SAF problems with concentration ≥ 4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.

    Time frame: At Week 32

  18. Change From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MPN-SAF TSS 10

    MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as a baseline MPN-SAF problems with concentration ≥ 4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.

    Time frame: Baseline to end of study (up to approximately 5 years)

  19. Change From Baseline in Patient Global Impression of Severity (PGI-S) at Each Scheduled Assessment

    The PGI-S is a single question to assess the severity of PV symptoms over the last 24 hours prior to dosing. The participant will determine the severity of their PV symptoms on a 4-point scale ranging from "None" (0) to "Severe" (3). A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

    Time frame: Baseline to end of study (up to approximately 5 years)

  20. Percentage of Participants With at Least One Unit Improvement in the PGI-S From Baseline at Each Scheduled Assessment

    The PGI-S is a single question to assess the severity of PV symptoms over the last 24 hours prior to dosing. The participant will determine the severity of their PV symptoms on a 4-point scale ranging from "None" (0) to "Severe" (3). A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

    Time frame: Baseline to end of study (up to approximately 5 years)

  21. Percentage of Participants With a Rating on the Patient Global Impression of Change (PGI-C) of Either "Much Better" or "a Little Better" at Each Scheduled Assessment

    PGI-C is a simple, commonly used instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. Participants will compare his/her condition from the start of the study on a 5-point scale ranging from "Much better" (1) to "Much worse" (5) at the time of the assessment.

    Time frame: Baseline to end of study (up to approximately 5 years)

  22. Mean PGI-C at Each Scheduled Assessment

    PGI-C is a simple, commonly used instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. Participants will compare his/her condition from the start of the study on a 5-point scale ranging from "Much better" (1) to "Much worse" (5) at the time of the assessment. A higher score indicates a worse condition.

    Time frame: Baseline to end of study (up to approximately 5 years)

  23. Change From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 Total Symptom Score-7 Items (TSS7)

    The MFSAF version 4.0 (v4.0) TSS7 is a questionnaire developed by the Patient-Reported Outcome (PRO) Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

    Time frame: Baseline to end of study (up to approximately 5 years)

  24. Change From Baseline in the Individual Domain Scores and the Total European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score

    The EORTC QLQ-C30 is a validated instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. It consists of 5 functional scales (physical, role, cognitive, emotional, and social functioning), a global quality of life (QoL) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (appetite loss, diarrhea, dyspnea, constipation, insomnia, financial impact). For the functional and the global QoL scales, a higher score indicates better health. For the symptom scales, a higher score indicates more symptom burden. The QLQ-C30 summary score is calculated as the mean of the combined 13 QLQ-C30 scale and item scores (excluding global QoL and financial impact), with a higher score indicating a better health related QoL. Raw scores are converted into scale scores ranging from 0 to 100.

    Time frame: Baseline, Week 32

  25. Median Time to First Hematocrit Equal to or Greater Than 45% After Randomization

    Time frame: Baseline to end of study (up to approximately 5 years)

  26. Median Time to Phlebotomy-eligible After Randomization

    Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

    Time frame: Baseline to end of study (up to approximately 5 years)

  27. Percentage of Participants With at Least One Hematocrit Equal to or Greater Than 48%

    Time frame: Baseline to end of study (up to approximately 5 years)

  28. Percentage of Participants Who Maintain Absence of Phlebotomy Eligibility

    Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

    Time frame: Baseline to end of study (up to approximately 5 years)

  29. Phlebotomy Annualized Rate

    Time frame: Baseline to end of study (up to approximately 5 years)

  30. Parts 1a + 1b: Percentage of Participants Originally Randomized to Rusfertide Achieving Absence of Phlebotomy Eligibility More Than 52 Weeks

    Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

    Time frame: Baseline to Week 52

  31. Part 1b: Median Time to First Hematocrit Equal to or Greater Than 45%

    Time frame: Week 32 to Week 52

  32. Part 1b: Median Time to First Phlebotomy

    Time frame: Week 32 to Week 52

  33. Parts 1a + 1b: Percentage of Participants With All Hematocrit Values Less Than 45%

    Time frame: Baseline to Week 52

  34. Parts 1a + 1b: Percentage of Participants Randomized to Placebo Who Meet the Phlebotomy Eligibility in Part 1a and Part 1b, Separately

    Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

    Time frame: Baseline to Week 52

  35. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline up to end of study (up to approximately 5 years)

07

Results

Posted Oct 19, 2026

Participant flow

A total of 293 participants participated in this study across 102 sites starting on 11 April 2022. This study is ongoing. Included here are the primary results.

Part 1a: Double-Blind Period
Participant flow — Part 1a: Double-Blind Period
MilestonePart 1a: Randomized, Double-Blind Period: PlaceboPart 1a: Randomized, Double-Blind Period: RusfertidePart 1b: Open-Label Treatment Period: RusfertidePart 2: Long Term Extension Period: Rusfertide
Started14614700
Completed14113400
Not completed51300
Withdrew: Adverse event4800
Withdrew: Disease progression1000
Withdrew: Withdrawal by subject0300
Withdrew: Randomized but not treated0200
Part 1b: Open-Label Treatment Period
Participant flow — Part 1b: Open-Label Treatment Period
MilestonePart 1a: Randomized, Double-Blind Period: PlaceboPart 1a: Randomized, Double-Blind Period: RusfertidePart 1b: Open-Label Treatment Period: RusfertidePart 2: Long Term Extension Period: Rusfertide
Started002740
Completed002670
Not completed0070
Withdrew: Adverse event0030
Withdrew: Lack of efficacy0020
Withdrew: Reason not specified0010
Withdrew: Withdrawal by subject0010
Part 2: Long Term Extension Period
Participant flow — Part 2: Long Term Extension Period
MilestonePart 1a: Randomized, Double-Blind Period: PlaceboPart 1a: Randomized, Double-Blind Period: RusfertidePart 1b: Open-Label Treatment Period: RusfertidePart 2: Long Term Extension Period: Rusfertide
Started000267
Completed0000
Not completed000267
Withdrew: Study ongoing000254
Withdrew: Adverse event0004
Withdrew: Disease progression0002
Withdrew: Lack of efficacy0002
Withdrew: Withdrawal by subject0004
Withdrew: Reason not specified0001

Outcome measures

PrimaryPart 1a: Percentage of Participants Who Achieved Response

Response was defined as absence of phlebotomy eligibility. Phlebotomy eligibility was defined as either: 1) A confirmed hematocrit (HCT) greater than or equal to (≥) 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

Time frame:
From Weeks 20 to 32
Reported as:
Number · percentage of participants
Part 1a: Percentage of Participants Who Achieved Response
percentage of participantsPart 1a: Randomized, Double-Blind Period: PlaceboPart 1a: Randomized, Double-Blind Period: Rusfertide
Part 1a: Percentage of Participants Who Achieved Response32.976.9
Statistical analysis
  • Part 1a: Randomized, Double-Blind Period: Placebo vs Part 1a: Randomized, Double-Blind Period: Rusfertide · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 6.42 · 95% CI 3.81 to 10.80P-value was obtained from the Cochran-Mantel-Haenszel test stratified by ongoing PV therapy.
SecondaryPart 1a: Number of Phlebotomies
Time frame:
Baseline to Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Percentage of Participants With All Hematocrit Values < 45%
Time frame:
Baseline to Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a Total T-score

The PROMIS Fatigue SF 8a T-score will be obtained via the item-response theory (IRT) response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Change From Baseline in the Myelofibrosis Symptom Assessment Form (MFSAF) Version 4.0 Total Symptom Score-7 (TSS7) Items

The MFSAF version 4.0 (v4.0) TSS7 is a questionnaire developed by the Patient-Reported Outcome (PRO) Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Change From Baseline in the PROMIS Fatigue Short Form 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at Baseline

The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is a National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Change From Baseline in the MFSAF Total Symptom Score-4 Items (TSS4) Among Participants Who Have Moderate or Severe Symptoms at Baseline

The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focused on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. Items are scored on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

Time frame:
Baseline, Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Change From Baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Problems With Concentration Among Participants Who Have Moderate or Severe Symptoms at Baseline

MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as baseline MPN-SAF problems with concentration ≥4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline will be categorized using the Patient Global Impression of Severity (PGI-S). The response quartiles will be used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.

Time frame:
Baseline, Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at Baseline

The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8.

Time frame:
At Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4 Among Participants Who Had Moderate or Severe Symptoms at Baseline

The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It included 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1.

Time frame:
At Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With Concentration Among Participants Who Had Moderate or Severe Symptoms at Baseline

MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as baseline MPN-SAF problems with concentration ≥4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.

Time frame:
At Week 32

Results for this outcome have not been posted.

SecondaryChange From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue SF 8a

The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey that includes 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue Short Form 8a for Among Participants With Moderate or Severe Symptoms at Baseline

The PROMIS Fatigue SF 8a T-score was obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is a National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8. A negative change from baseline indicates an improvement.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MFSAF v4.0 TSS4

The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 TSS4 Among Participants With Moderate or Severe Symptoms at Baseline

The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focused on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. Items are scored on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-score

The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey that includes 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. A negative change from baseline indicates an improvement.

Time frame:
At Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4

The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive).

Time frame:
At Week 32

Results for this outcome have not been posted.

SecondaryPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With Concentration

MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as a baseline MPN-SAF problems with concentration ≥ 4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.

Time frame:
At Week 32

Results for this outcome have not been posted.

SecondaryChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MPN-SAF TSS 10

MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as a baseline MPN-SAF problems with concentration ≥ 4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline in Patient Global Impression of Severity (PGI-S) at Each Scheduled Assessment

The PGI-S is a single question to assess the severity of PV symptoms over the last 24 hours prior to dosing. The participant will determine the severity of their PV symptoms on a 4-point scale ranging from "None" (0) to "Severe" (3). A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryPercentage of Participants With at Least One Unit Improvement in the PGI-S From Baseline at Each Scheduled Assessment

The PGI-S is a single question to assess the severity of PV symptoms over the last 24 hours prior to dosing. The participant will determine the severity of their PV symptoms on a 4-point scale ranging from "None" (0) to "Severe" (3). A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryPercentage of Participants With a Rating on the Patient Global Impression of Change (PGI-C) of Either "Much Better" or "a Little Better" at Each Scheduled Assessment

PGI-C is a simple, commonly used instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. Participants will compare his/her condition from the start of the study on a 5-point scale ranging from "Much better" (1) to "Much worse" (5) at the time of the assessment.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryMean PGI-C at Each Scheduled Assessment

PGI-C is a simple, commonly used instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. Participants will compare his/her condition from the start of the study on a 5-point scale ranging from "Much better" (1) to "Much worse" (5) at the time of the assessment. A higher score indicates a worse condition.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 Total Symptom Score-7 Items (TSS7)

The MFSAF version 4.0 (v4.0) TSS7 is a questionnaire developed by the Patient-Reported Outcome (PRO) Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryChange From Baseline in the Individual Domain Scores and the Total European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score

The EORTC QLQ-C30 is a validated instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. It consists of 5 functional scales (physical, role, cognitive, emotional, and social functioning), a global quality of life (QoL) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (appetite loss, diarrhea, dyspnea, constipation, insomnia, financial impact). For the functional and the global QoL scales, a higher score indicates better health. For the symptom scales, a higher score indicates more symptom burden. The QLQ-C30 summary score is calculated as the mean of the combined 13 QLQ-C30 scale and item scores (excluding global QoL and financial impact), with a higher score indicating a better health related QoL. Raw scores are converted into scale scores ranging from 0 to 100.

Time frame:
Baseline, Week 32

Results for this outcome have not been posted.

SecondaryMedian Time to First Hematocrit Equal to or Greater Than 45% After Randomization
Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryMedian Time to Phlebotomy-eligible After Randomization

Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryPercentage of Participants With at Least One Hematocrit Equal to or Greater Than 48%
Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Maintain Absence of Phlebotomy Eligibility

Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryPhlebotomy Annualized Rate
Time frame:
Baseline to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

SecondaryParts 1a + 1b: Percentage of Participants Originally Randomized to Rusfertide Achieving Absence of Phlebotomy Eligibility More Than 52 Weeks

Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

Time frame:
Baseline to Week 52

Results for this outcome have not been posted.

SecondaryPart 1b: Median Time to First Hematocrit Equal to or Greater Than 45%
Time frame:
Week 32 to Week 52

Results for this outcome have not been posted.

SecondaryPart 1b: Median Time to First Phlebotomy
Time frame:
Week 32 to Week 52

Results for this outcome have not been posted.

SecondaryParts 1a + 1b: Percentage of Participants With All Hematocrit Values Less Than 45%
Time frame:
Baseline to Week 52

Results for this outcome have not been posted.

SecondaryParts 1a + 1b: Percentage of Participants Randomized to Placebo Who Meet the Phlebotomy Eligibility in Part 1a and Part 1b, Separately

Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.

Time frame:
Baseline to Week 52

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame:
Baseline up to end of study (up to approximately 5 years)

Results for this outcome have not been posted.

Adverse events

Collected over Part 1a: From Baseline up to Week 32; Part 1b: From Week 32 to Week 52, Part 2: From Week 52 up to data cut-off date 21 February 2025 (approximately 2 years); Part 2 is ongoing. Part 3 has not started as of data cutoff date 21 February 2025. Adverse events are still being collected and will be updated one year after study completion date.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1a: Randomized, Placebo-Controlled Period: Placebo0/146 (0%)7/146 (4.8%)101/146 (69.2%)
Part 1a: Randomized, Placebo-Controlled Period: Rusfertide0/147 (0%)5/145 (3.4%)115/145 (79.3%)
Part 1b: Open-Label Treatment Phase0/274 (0%)7/274 (2.6%)139/274 (50.7%)
Part 2: Long Term Extension0/267 (0%)10/266 (3.8%)104/266 (39.1%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
EventPart 1a: Randomized, Placebo-Controlled Period: PlaceboPart 1a: Randomized, Placebo-Controlled Period: RusfertidePart 1b: Open-Label Treatment PhasePart 2: Long Term Extension
Acute myocardial infarctionCardiac disorders0/1461/1450/2741/266
Blood glucose increasedInvestigations0/1461/1450/2740/266
Diabetic ketoacidosisMetabolism and nutrition disorders0/1461/1450/2740/266
HaematomaVascular disorders0/1461/1450/2740/266
HaematuriaRenal and urinary disorders0/1461/1451/2740/266
Bullous erysipelasInfections and infestations1/1460/1450/2740/266
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1460/1450/2740/266
DiarrhoeaGastrointestinal disorders1/1460/1450/2740/266
Drug hypersensitivityImmune system disorders1/1460/1450/2740/266
HeadacheNervous system disorders1/1460/1450/2740/266
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPart 1a: Randomized, Placebo-Controlled Period: PlaceboPart 1a: Randomized, Placebo-Controlled Period: RusfertidePart 1b: Open-Label Treatment PhasePart 2: Long Term Extension
Injection site erythemaGeneral disorders11/14645/14531/27412/266
Injection site pruritusGeneral disorders4/14626/14519/2745/266
FatigueGeneral disorders23/14622/14526/27414/266
Injection site painGeneral disorders23/14620/14518/2749/266
AnaemiaBlood and lymphatic system disorders6/14622/14529/27432/266
COVID-19Infections and infestations16/14614/1456/2744/266
HeadacheNervous system disorders16/14615/1458/27410/266
PruritusSkin and subcutaneous tissue disorders15/14615/1458/2749/266
DiarrhoeaGastrointestinal disorders9/14612/1458/27414/266
DizzinessNervous system disorders9/14612/1454/27411/266

Baseline characteristics

The Intent-to-Treat (ITT) Set comprised all randomized participants according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(years)Part 1a: Randomized, Double-Blind Period: PlaceboPart 1a: Randomized, Double-Blind Period: RusfertideTotal
Mean57.3 ± 10.4556.7 ± 12.2057 ± 11.35
Sex: Female, Male
Sex: Female, Male(Participants)Part 1a: Randomized, Double-Blind Period: PlaceboPart 1a: Randomized, Double-Blind Period: RusfertideTotal
Female384179
Male108106214
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1a: Randomized, Double-Blind Period: PlaceboPart 1a: Randomized, Double-Blind Period: RusfertideTotal
Hispanic or Latino6814
Not Hispanic or Latino132134266
Unknown or Not Reported8513
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1a: Randomized, Double-Blind Period: PlaceboPart 1a: Randomized, Double-Blind Period: RusfertideTotal
White133129262
Black or African American112
Asian459
American Indian or Alaska Native202
Native Hawaiian or Other Pacific Islander000
Multiple000
Not Reported4610
Other167
Unknown101
08

Study locations

184 sites

Showing the first 100 of 184 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2022 to primary completion in Feb 2025, 34 months.

Results were first posted in Oct 2026, 1 year 7 months after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Aug 2028, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2022
First posted
Jan 27, 2022
StartActual
Apr 11, 2022
Primary completionActual
Feb 21, 2025
CompletionEst.
Aug 31, 2028was Jun 2027
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 19, 2026
Start date
Apr 1, 2022→Apr 11, 2022
Oct 19, 2026
Study completion
Jun 2027→Aug 31, 2028
Oct 19, 2026
Eligibility
7 inclusion criteria edited, 15 added; 5 exclusion criteria edited, 15 added; 2 criteria removed
What changed in the criteria
  • RemovedMain Inclusion Criteria: All subjects must meet ALL of the following inclusion criteria to be enrolled. There are additional inclusion criteria.
  • RemovedMain Exclusion Criteria: Subjects must meet NONE of the following exclusion criteria to be enrolled. There are additional exclusion criteria.
Inclusion criteria
  • EditedMale and female subjectsparticipants aged 18 (or the minimum country specific minimum age of consent if greater than [>]18) years or older.
  • AddedParticipant understands the study procedures, is willing and able to adhere to study requirements and agrees to participate in the study by giving written informed consent.
  • EditedMeet revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia veraPV.
  • AddedPhlebotomy requiring defined as ALL of the following:
  • EditedAt least 3 phlebotomies due to inadequate hematocrit control in 6 months28 weeks before randomization or at least 5 phlebotomies due to inadequate hematocrit control in 1 year before randomization., and
  • AddedLast phlebotomy due to inadequate hematocrit control within 3 months before randomization, and
  • AddedNo phlebotomy within 6 days prior to randomization (do not include day of phlebotomy and day of randomization in the 6-day count).
  • EditedComplete blood count (CBC) values immediately prior to randomization:
  • EditedWhite blood cell count (WBC) 4000 cells per microlitre (/μL) to 20,000/μL (inclusive), and
  • AddedEastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
  • AddedWomen of childbearing potential (WOCBP) agree to use medically acceptable contraception (<1% annual failure rate) during the study and for 30 days after the last dose of study drug.
  • AddedA female participant must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 30 days after receiving the last dose of study medication.
  • AddedMen with partners of childbearing potential agree to use medically acceptable contraception (<1% annual failure rate) during the study and for 90 days after the last dose of study drug. In addition, men must use a condom during the study and for 90 days after the last dose of study drug regardless of the partner's childbearing potential.
  • AddedA male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose.
  • EditedSubjectsParticipants receiving cytoreductive therapy at randomization must be on a stable PV therapy regimen. as follows:
  • AddedHydroxyurea - at least 2 months
  • AddedJanus kinase (JAK) inhibitor - at least 2 months
  • AddedInterferon - at least 6 months.
  • EditedSubjectsParticipants treated with phlebotomy alone at randomization must have stopped cytoreductive therapy 2 to 6 months before screening.:
  • AddedHydroxyurea at least 2 months before screening
  • AddedJAK inhibitor at least 2 months before screening
  • AddedInterferon at least 6 months before screening.
Exclusion criteria
  • EditedClinically meaningful laboratory abnormalities at Screening., including but not limited to the following:
  • AddedEstimated glomerular filtration rate (eGFR) <15 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2)
  • AddedAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.5×upper limit of normal (ULN)
  • AddedTotal bilirubin >1.5×ULN
  • EditedSubjectsParticipants who requirerequired phlebotomy at hematocritHCT levels lower than 45%.
  • AddedPregnant or lactating females.
  • AddedMet the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment.
  • AddedAny infection requiring systemic therapy within 1 month of dosing except controlled human immunodeficiency virus (HIV), hepatitis B, and hepatitis C. Prophylactic therapies were allowed.
  • AddedAny serious or unstable medical condition (e.g., poorly controlled HIV infection) or uncontrolled psychiatric condition as judged by the Investigator that would impair the participant's ability to participate in the study.
  • AddedMajor surgical procedure within 2 months prior to randomization unless the participant had fully recovered from surgery or planned major elective surgery during the study.
  • EditedHistory of invasive malignancies within the last 5 years, except localized cured prostate cancer and cervical cancer.
  • Addedlocalized cured cancer (e.g., prostate cancer and cervical cancer)
  • EditedSubjects withlocalized cured in situ or stageStage 1 squamous cell carcinoma (SCC) of the skin, in situ or stage 1 basal cell carcinoma (BCC) of the skin, or in situ melanoma of the skin identified during screen unless the cancer is adequately treated before randomization.
  • AddedParticipants with in situ or Stage 1 SCC of the skin, in situ or Stage 1 BCC of the skin, or in situ melanoma of the skin identified during the required dermatology examination at Screening unless the cancer was adequately treated (i.e., treatment that was expected to be curative, such as Mohs surgery) before randomization. Note: Suspicious lesions were to be biopsied and results made available before randomization.
  • AddedParticipants with active alcohol or drug addiction that would have interfered with their ability to comply with study requirements.
  • AddedParticipants who did not complete at least 4 days of MFSAF assessments within 1 week prior to randomization.

…and 4 more changes, on the record history on ClinicalTrials.gov ↗

Oct 19, 2026
Interventions
Arm changed Placebo→Part 1a: Randomized, Double-Blind Period: Placebo. Arms added: Part 1a: Randomized, Double-Blind Period: Rusfertide·Part 1b: Open-Label Treatment Period: Rusfertide·Part 2: Long Term Extension Period: Rusfertide·Part 3: Treatment Extension Period: Rusfertide; arms removed: Rusfertide
Oct 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Proportion of subjects achieving a response who receive rusfertide compared to placebo.Now Part 1a: Percentage of Participants Who Achieved ResponseTime frame: Week 20 through Week 32 → From Weeks 20 to 32
Oct 19, 2026
Documents
Secondary outcomes
30 added, 9 more
What changed in the outcomes
  • AddedPart 1a: Number of PhlebotomiesTime frame: Baseline to Week 32
  • AddedPart 1a: Percentage of Participants With All Hematocrit Values < 45%Time frame: Baseline to Week 32
  • AddedPart 1a: Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a Total T-scoreTime frame: Baseline, Week 32
  • AddedPart 1a: Change From Baseline in the Myelofibrosis Symptom Assessment Form (MFSAF) Version 4.0 Total Symptom Score-7 (TSS7) ItemsTime frame: Baseline, Week 32
  • AddedPart 1a: Change From Baseline in the PROMIS Fatigue Short Form 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at BaselineTime frame: Baseline, Week 32
  • AddedPart 1a: Change From Baseline in the MFSAF Total Symptom Score-4 Items (TSS4) Among Participants Who Have Moderate or Severe Symptoms at BaselineTime frame: Baseline, Week 32
  • AddedPart 1a: Change From Baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Problems With Concentration Among Participants Who Have Moderate or Severe Symptoms at BaselineTime frame: Baseline, Week 32
  • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at BaselineTime frame: At Week 32
  • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4 Among Participants Who Had Moderate or Severe Symptoms at BaselineTime frame: At Week 32
  • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With Concentration Among Participants Who Had Moderate or Severe Symptoms at BaselineTime frame: At Week 32
  • AddedChange From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue SF 8aTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedChange From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue Short Form 8a for Among Participants With Moderate or Severe Symptoms at BaselineTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MFSAF v4.0 TSS4Time frame: Baseline to end of study (up to approximately 5 years)
  • AddedChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 TSS4 Among Participants With Moderate or Severe Symptoms at BaselineTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-scoreTime frame: At Week 32
  • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4Time frame: At Week 32
  • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With ConcentrationTime frame: At Week 32
  • AddedChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MPN-SAF TSS 10Time frame: Baseline to end of study (up to approximately 5 years)
  • AddedChange From Baseline in Patient Global Impression of Severity (PGI-S) at Each Scheduled AssessmentTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedPercentage of Participants With at Least One Unit Improvement in the PGI-S From Baseline at Each Scheduled AssessmentTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedPercentage of Participants With a Rating on the Patient Global Impression of Change (PGI-C) of Either "Much Better" or "a Little Better" at Each Scheduled AssessmentTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedMean PGI-C at Each Scheduled AssessmentTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 Total Symptom Score-7 Items (TSS7)Time frame: Baseline to end of study (up to approximately 5 years)
  • AddedChange From Baseline in the Individual Domain Scores and the Total European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) ScoreTime frame: Baseline, Week 32
  • AddedMedian Time to First Hematocrit Equal to or Greater Than 45% After RandomizationTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedMedian Time to Phlebotomy-eligible After RandomizationTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedPercentage of Participants With at Least One Hematocrit Equal to or Greater Than 48%Time frame: Baseline to end of study (up to approximately 5 years)
  • AddedPercentage of Participants Who Maintain Absence of Phlebotomy EligibilityTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedPhlebotomy Annualized RateTime frame: Baseline to end of study (up to approximately 5 years)
  • AddedParts 1a + 1b: Percentage of Participants Originally Randomized to Rusfertide Achieving Absence of Phlebotomy Eligibility More Than 52 WeeksTime frame: Baseline to Week 52
  • …and 9 more, on the record history on ClinicalTrials.gov ↗
Oct 19, 2026
Title
A Phase 3 Study of Rusfertide in PatientsAdults With Polycythemia Vera (PV)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Results posted
    Start date Apr 1, 2022→Apr 11, 2022
    Study completion Jun 2027→Aug 31, 2028
    Eligibility 7 inclusion criteria edited, 15 added; 5 exclusion criteria edited, 15 added; 2 criteria removed
    What changed in the criteria
    • RemovedMain Inclusion Criteria: All subjects must meet ALL of the following inclusion criteria to be enrolled. There are additional inclusion criteria.
    • RemovedMain Exclusion Criteria: Subjects must meet NONE of the following exclusion criteria to be enrolled. There are additional exclusion criteria.
    Inclusion criteria
    • EditedMale and female subjectsparticipants aged 18 (or the minimum country specific minimum age of consent if greater than [>]18) years or older.
    • AddedParticipant understands the study procedures, is willing and able to adhere to study requirements and agrees to participate in the study by giving written informed consent.
    • EditedMeet revised 2016 World Health Organization (WHO) criteria for the diagnosis of polycythemia veraPV.
    • AddedPhlebotomy requiring defined as ALL of the following:
    • EditedAt least 3 phlebotomies due to inadequate hematocrit control in 6 months28 weeks before randomization or at least 5 phlebotomies due to inadequate hematocrit control in 1 year before randomization., and
    • AddedLast phlebotomy due to inadequate hematocrit control within 3 months before randomization, and
    • AddedNo phlebotomy within 6 days prior to randomization (do not include day of phlebotomy and day of randomization in the 6-day count).
    • EditedComplete blood count (CBC) values immediately prior to randomization:
    • EditedWhite blood cell count (WBC) 4000 cells per microlitre (/μL) to 20,000/μL (inclusive), and
    • AddedEastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
    • AddedWomen of childbearing potential (WOCBP) agree to use medically acceptable contraception (<1% annual failure rate) during the study and for 30 days after the last dose of study drug.
    • AddedA female participant must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 30 days after receiving the last dose of study medication.
    • AddedMen with partners of childbearing potential agree to use medically acceptable contraception (<1% annual failure rate) during the study and for 90 days after the last dose of study drug. In addition, men must use a condom during the study and for 90 days after the last dose of study drug regardless of the partner's childbearing potential.
    • AddedA male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after receiving the last dose.
    • EditedSubjectsParticipants receiving cytoreductive therapy at randomization must be on a stable PV therapy regimen. as follows:
    • AddedHydroxyurea - at least 2 months
    • AddedJanus kinase (JAK) inhibitor - at least 2 months
    • AddedInterferon - at least 6 months.
    • EditedSubjectsParticipants treated with phlebotomy alone at randomization must have stopped cytoreductive therapy 2 to 6 months before screening.:
    • AddedHydroxyurea at least 2 months before screening
    • AddedJAK inhibitor at least 2 months before screening
    • AddedInterferon at least 6 months before screening.
    Exclusion criteria
    • EditedClinically meaningful laboratory abnormalities at Screening., including but not limited to the following:
    • AddedEstimated glomerular filtration rate (eGFR) <15 milliliters per minute per 1.73 square meters (mL/min/1.73 m\^2)
    • AddedAlanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.5×upper limit of normal (ULN)
    • AddedTotal bilirubin >1.5×ULN
    • EditedSubjectsParticipants who requirerequired phlebotomy at hematocritHCT levels lower than 45%.
    • AddedPregnant or lactating females.
    • AddedMet the criteria for post-PV myelofibrosis as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment.
    • AddedAny infection requiring systemic therapy within 1 month of dosing except controlled human immunodeficiency virus (HIV), hepatitis B, and hepatitis C. Prophylactic therapies were allowed.
    • AddedAny serious or unstable medical condition (e.g., poorly controlled HIV infection) or uncontrolled psychiatric condition as judged by the Investigator that would impair the participant's ability to participate in the study.
    • AddedMajor surgical procedure within 2 months prior to randomization unless the participant had fully recovered from surgery or planned major elective surgery during the study.
    • EditedHistory of invasive malignancies within the last 5 years, except localized cured prostate cancer and cervical cancer.
    • Addedlocalized cured cancer (e.g., prostate cancer and cervical cancer)
    • EditedSubjects withlocalized cured in situ or stageStage 1 squamous cell carcinoma (SCC) of the skin, in situ or stage 1 basal cell carcinoma (BCC) of the skin, or in situ melanoma of the skin identified during screen unless the cancer is adequately treated before randomization.
    • AddedParticipants with in situ or Stage 1 SCC of the skin, in situ or Stage 1 BCC of the skin, or in situ melanoma of the skin identified during the required dermatology examination at Screening unless the cancer was adequately treated (i.e., treatment that was expected to be curative, such as Mohs surgery) before randomization. Note: Suspicious lesions were to be biopsied and results made available before randomization.
    • AddedParticipants with active alcohol or drug addiction that would have interfered with their ability to comply with study requirements.
    • AddedParticipants who did not complete at least 4 days of MFSAF assessments within 1 week prior to randomization.

    …and 4 more changes, on the record history on ClinicalTrials.gov ↗

    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Proportion of subjects achieving a response who receive rusfertide compared to placebo.Now Part 1a: Percentage of Participants Who Achieved ResponseTime frame: Week 20 through Week 32 → From Weeks 20 to 32
    Secondary outcomes 30 added, 9 more
    What changed in the outcomes
    • AddedPart 1a: Number of PhlebotomiesTime frame: Baseline to Week 32
    • AddedPart 1a: Percentage of Participants With All Hematocrit Values < 45%Time frame: Baseline to Week 32
    • AddedPart 1a: Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a Total T-scoreTime frame: Baseline, Week 32
    • AddedPart 1a: Change From Baseline in the Myelofibrosis Symptom Assessment Form (MFSAF) Version 4.0 Total Symptom Score-7 (TSS7) ItemsTime frame: Baseline, Week 32
    • AddedPart 1a: Change From Baseline in the PROMIS Fatigue Short Form 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at BaselineTime frame: Baseline, Week 32
    • AddedPart 1a: Change From Baseline in the MFSAF Total Symptom Score-4 Items (TSS4) Among Participants Who Have Moderate or Severe Symptoms at BaselineTime frame: Baseline, Week 32
    • AddedPart 1a: Change From Baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Problems With Concentration Among Participants Who Have Moderate or Severe Symptoms at BaselineTime frame: Baseline, Week 32
    • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at BaselineTime frame: At Week 32
    • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4 Among Participants Who Had Moderate or Severe Symptoms at BaselineTime frame: At Week 32
    • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With Concentration Among Participants Who Had Moderate or Severe Symptoms at BaselineTime frame: At Week 32
    • AddedChange From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue SF 8aTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedChange From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue Short Form 8a for Among Participants With Moderate or Severe Symptoms at BaselineTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MFSAF v4.0 TSS4Time frame: Baseline to end of study (up to approximately 5 years)
    • AddedChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 TSS4 Among Participants With Moderate or Severe Symptoms at BaselineTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-scoreTime frame: At Week 32
    • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4Time frame: At Week 32
    • AddedPart 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With ConcentrationTime frame: At Week 32
    • AddedChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MPN-SAF TSS 10Time frame: Baseline to end of study (up to approximately 5 years)
    • AddedChange From Baseline in Patient Global Impression of Severity (PGI-S) at Each Scheduled AssessmentTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedPercentage of Participants With at Least One Unit Improvement in the PGI-S From Baseline at Each Scheduled AssessmentTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedPercentage of Participants With a Rating on the Patient Global Impression of Change (PGI-C) of Either "Much Better" or "a Little Better" at Each Scheduled AssessmentTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedMean PGI-C at Each Scheduled AssessmentTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedChange From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 Total Symptom Score-7 Items (TSS7)Time frame: Baseline to end of study (up to approximately 5 years)
    • AddedChange From Baseline in the Individual Domain Scores and the Total European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) ScoreTime frame: Baseline, Week 32
    • AddedMedian Time to First Hematocrit Equal to or Greater Than 45% After RandomizationTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedMedian Time to Phlebotomy-eligible After RandomizationTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedPercentage of Participants With at Least One Hematocrit Equal to or Greater Than 48%Time frame: Baseline to end of study (up to approximately 5 years)
    • AddedPercentage of Participants Who Maintain Absence of Phlebotomy EligibilityTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedPhlebotomy Annualized RateTime frame: Baseline to end of study (up to approximately 5 years)
    • AddedParts 1a + 1b: Percentage of Participants Originally Randomized to Rusfertide Achieving Absence of Phlebotomy Eligibility More Than 52 WeeksTime frame: Baseline to Week 52
    • …and 9 more, on the record history on ClinicalTrials.gov ↗
    Interventions Arm changed Placebo→Part 1a: Randomized, Double-Blind Period: Placebo. Arms added: Part 1a: Randomized, Double-Blind Period: Rusfertide·Part 1b: Open-Label Treatment Period: Rusfertide·Part 2: Long Term Extension Period: Rusfertide·Part 3: Treatment Extension Period: Rusfertide; arms removed: Rusfertide
    Title A Phase 3 Study of Rusfertide in PatientsAdults With Polycythemia Vera (PV)
    + 8 other changes: verification date, oversight details, description, design details, site details, contact details, references and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05210790
Lead sponsor
Protagonist Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 27, 2022
Start date
Apr 11, 2022
Primary completion
Feb 21, 2025
Completion
Aug 31, 2028 (estimated)
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rusfertide

Start the discussion